Products
Satralizumab was approved in many countries in 2020 as a solution for injection (Enspryng).
Structure and properties
Satralizumab is a humanized IgG2 monoclonal antibody produced by biotechnological methods.
Effects
Satralizumab (ATC L04AC19) has anti-inflammatory and immunosuppressive properties. The effects are due to binding to the soluble and membrane-bound human IL-6 receptor (IL-6R), preventing signal transduction by IL-6. IL-6 is a cytokine that activates immune cells and promotes inflammation and autoantibody formation. The antibody has a long half-life of about 30 days.
Indications
For the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adults and adolescents in whom aquaporin-4 IgG antibodies are detectable.
Dosage
According to the SmPC. The drug is administered as a subcutaneous injection.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
CYP450 isoenzyme expression may change during treatment.
Adverse effects
The most common potential adverse effects include headache, joint pain, leukopenia, and injection-related reactions.
